Latest:
Confusion Persists Around the Interchangeability Designation for Biosimilars
The legal and common uses of “interchangeability” continue to be conflated.
© 2025 MJH Life Sciences™ and The Center for Biosimilars - Biosimilars, Health Economics & Insights. All rights reserved.
Authors
Prateek Yadav, MPTh, MBA
Prateek Yadav, MPTh, MBA, a manager at
Latest:
The Next Frontier: Oncology Biosimilars in 2025 and Beyond
The US oncology biosimilar market has rapidly evolved since its launch in 2017, driven by steep price discounts, payer adoption, and provider confidence, with an upcoming wave of biosimilars targeting blockbuster biologics promising further market growth, cost savings, and broader patient access.
Mark Campbell, PharmD
Mark Campbell, PharmD, is the chief pharmacy officer at RxBenefits.
Latest:
A Promise Unfulfilled: The State of Biosimilars
For biosimilars to overcome these entrenched market dynamics, they must not only compete on price but actively work to build a network of support among providers and patients.
Paul Cornes, BM, BCH, MA, MRCP, FRCR
Paul Cornes, BM, BCH, MA, MRCP, FRCR, is a consultant oncologist and biosimilars expert who was part of the team that developed and presented evidence to the FDA for the first successfullly approved US biosimilar.
Latest:
Column: India Struggles to Meet International Biologics Standards
An internationally recognized authority on biosimilar development discusses varieties of copy biologics in India and the need to distinguish these from true biosimilars.
Meaghan Smith
Meaghan Smith is the executive director of the Biosimilars Forum. She previously served as a senior adviser and communications director at HHS during the Obama administration.
Latest:
Opinion: Biosimilars Offer Savings and Access for US Patients
In this column, officials from the Biosimilars Forum and Xcenda discuss how biosimilar competition has lowered prices of originator biologics and improved patient access.
Monica Mallampalli, PhD, MSc
Monica Mallampalli, PhD, MSc, is senior advisor for Scientific and Strategy Initiatives at HealthyWomen.
Latest:
Biosimilars and Women's Health: Realizing the Potential
The potential and promise of biosimilars are there—it is up to all of us to bring it to reality so we can expand access to safe, effective, affordable drugs for women.
Robert Spina, MBA
Robert Spina, MBA, is vice president of Marketing, Market Access, and Patient Services at Sandoz.
Latest:
Opinion: Support Health Equity and Access to Health Care With More Affordable Treatment Options
Changes in federal and state policy can help liberate the savings potential in biosimilars and broaden investment in our health care system.
Advertisement
Advertisement